STAA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
STAA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Staar Surgical Co's enterprise value is $1,812.8 Mil. Staar Surgical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $28.3 Mil. Therefore, Staar Surgical Co's EV-to-EBITDA for today is 64.15.
The historical rank and industry rank for Staar Surgical Co's EV-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest EV-to-EBITDA of Staar Surgical Co was 602.48. The lowest was -2501.69. And the median was 82.21.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-25), Staar Surgical Co's stock price is $41.16. Staar Surgical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.310. Therefore, Staar Surgical Co's PE Ratio for today is 132.77.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Staar Surgical Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Staar Surgical Co Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | 94.27 | 358.67 | 113.27 | 44.70 | 40.32 |
Staar Surgical Co Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EV-to-EBITDA | Get a 7-Day Free Trial | 74.62 | 76.84 | 75.53 | 40.32 | 58.75 |
For the Medical Instruments & Supplies subindustry, Staar Surgical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Staar Surgical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Staar Surgical Co's EV-to-EBITDA falls into.
Staar Surgical Co's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 1812.782 | / | 28.257 | |
= | 64.15 |
Staar Surgical Co's current Enterprise Value is $1,812.8 Mil.
Staar Surgical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $28.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Staar Surgical Co (NAS:STAA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Staar Surgical Co's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 41.16 | / | 0.310 | |
= | 132.77 |
Staar Surgical Co's share price for today is $41.16.
Staar Surgical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.310.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Staar Surgical Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Broadwood Partners Lp | 10 percent owner | BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019 |
Elizabeth Yeu Lin | director | 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630 |
Aimee S Weisner | director | ONE EDWARDS WAY, IRVINE CA 92614 |
Warren Foust | officer: Chief Operating Officer | 17 MAGNOLIA DRIVE, LADERA RANCH CA 92694 |
Magda Michna | officer: Chief Clinical, Regulatory, | C/O PRESBIA, 8845 IRVINE CENTER DRIVE, SUITE 100, IRVINE CA 92618 |
Keith Holliday | officer: V.P., Research & Development | 1911 WALKER AVENUE, MONROVIA CA 91016 |
Robert Studholme | officer: Senior VP, Operations | 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630 |
James E Francese | officer: VP, Global Marketing | 1911 WALKER AVE, MONROVIA CA 91016 |
Caren L Mason | director | 2523 PARK RIDGE DRIVE, ESCONDIDO CA 92025 |
Samuel J Gesten | officer: VP, General Counsel | 1911 WALKER AVENUE, MONROVIA CA 91016 |
Patrick F. Williams | officer: Chief Financial Officer | C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588 |
Hans-martin Blickensdoerfer | officer: VP, International Marketing | 1911 WALKER AVENUE, MONROVIA CA 91016 |
Lou Silverman | director | |
Graydon C. Hansen | officer: Sr. VP, Global Operations | 25651 ATLANTIC OCEAN DRIVE, LAKE FORST CA 92630 |
Jon K. Hayashida | officer: VP, Global Clinical, Medical | 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630 |
From GuruFocus
By GuruFocus Research GuruFocus Editor • 02-18-2023
By Business Wire • 08-02-2023
By Business Wire • 01-23-2024
By Business Wire • 12-04-2023
By Business Wire Business Wire • 01-09-2023
By Business Wire • 08-07-2023
By PRNewswire • 10-10-2023
By Business Wire Business Wire • 03-29-2023
By Business Wire Business Wire • 02-07-2023
By GuruFocus Research • 11-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.